James Love's blog

NSF, Gates Foundation policies on sharing data and intellectual property in agricultural basic research grant program (BREAD)

The US based National Science Foundation (NSF) and the Bill and Melinda Gates Foundation are collaborating on a program called Basic Research to Enable Agricultural Development (BREAD). A May 12, 2010 NSF announcement about the program is available here.

Cancer: Annual deaths compared to new cases in 2004, for 16 types of cancer and 4 World Bank income groups

The following table compares the annual deaths from cancer, to the annual incidence of the disease, broken down by cancer type and income group. The data in the table is annual deaths divided by annual incidence, show as a ratio.

For several types of cancer, there is not much difference in the reported ratios, between different income groups. For other types of cancer, the differences are large, and in favor of patients living in higher income countries. Cancer types with the largest disparities by income include the following:

  • Mouth and oropharynx cancers

Ratio of year 2000 breast cancer deaths to new breast cancer patients in Europe, by country and country income

The following graph presents the year 2000 raw mortality rate of breast cancer patients in 36 European Countries. The graph compares the ratio of breast cancer deaths to the annual incidence of breast cancer, to the per capita incomes in those countries, all based upon year 2000 data.

USTR's Request for Comments on ACTA

USTR has issued a request for comments on ACTA. The deadline for submissions is February 15, 2011. The notice gives very little guidance regarding the issues the USTR would like addressed in the comments.


[Billing Code 3190-W1-P]

Office of the United States Trade Representative

Anti-Counterfeiting Trade Agreement: Request for Comments from the Public

Agency: Office of the United States Trade Representative

Action: Request for written submissions from the public

Notes from meeting with USTR on the TPP IPR chapter

Today USTR provided some additional insight into negotiations of a regional, Asia-Pacific trade agreement, known as the Trans-Pacific Partnership (TPP) Agreement. The USTR web page on the TPP negotiations is http://www.ustr.gov/tpp. At present, the TPP negotiators include Australia, Brunei Darussalam, Chile, New Zealand, Peru, Singapore and Vietnam. Japan and Canada have expressed interest in joining the negotiations, and USTR clearly would like to design an agreement that will be open to other countries. Our discussions focused on the intellectual property chapter in the agreement.

NIH funded research involving trastuzumab (marketed by Roche under the trade name Herceptin)

13 December 2010

Drugs@FDA
Drug Name(s) HERCEPTIN (Brand Name Drug)
FDA Application No. (BLA) 103792
Active Ingredient(s) TRASTUZUMAB
Company GENENTECH (Roche acquired a majority ownership in 1990, and full ownership in March 2009.)
Original Approval or Tentative Approval Date September 25, 1998

What is Herceptin? How does it work?

Statements by KEI and others on NIH rejection of Fabrazyme March-In Request

For background on the Fabrazyme case, see: http://www.keionline.org/fabrazyme

The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at judit.rius@keionline.org if your organization would like to submit an statement.

Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)

Notes from EU Parliament meeting on innovation+access for medical technologies

Today I am attending a meeting at the European Parliament on new models of innovation for medical technologies. The event was organized by three MEPs, Thijs Berman, Eva Joly and Carl Schlyter, in collaboration with the European Parliament Working Group on Innovation, Access to Medicines and Poverity-Related Diseaes, and several consumer rights, public health and development NGOs (TACD, Health Action International, KEI, Oxfam and IQsensato).

Non-responsive letter from David Kappos of USPTO to Senators Sanders and Brown regarding ACTA consistency with US law

In a October 19, 2010, Senators Bernard Sanders (I-VT) and Sherrod Brown (D-OH) wrote to David Kappos, the Director of the USPTO, asking for an assessment of conflicts between the October 2010 ACTA text, and U.S. law. (attached here).

Kappos-200.jpg
Undersecretary of Commerce for
Intellectual Property, David Kappos

A KEI note to Library of Congress about ACTA text

From: James Love
To: Michele Woods
Cc: Nancy Weiss
Subject: Some examples of US inconsistency with ACTA
Date: Fri, 12 Nov 2010 07:29:09 -0500

This note cites several areas where US law is plainly inconsistent with
ACTA.

In addition, in a separate analysis,I have called attention to proposed
legislation in USA on orphan copyrighted works that are very
inconsistent with ACTA provisions on remedies.
http://www.keionline.org/node/980

Some examples of inconsistencies between ACTA and US law

The November 15, 2010 version of ACTA

The final conclusions for WIPO SCCR 21

Sometime very early Saturday morning, SCCR 21 ended with these conclusions.

KEI statement at SCCR 21

This was our 400 word statement at the WIPO SCCR 21.

Statement of KEI at WIPO SCCR 21, November 11, 2010

There should be a compelling rationale for creating new global norms for copyrights.

KEI opposes work on a new broadcasting treaty, and supports work on performers treaty.

KEI supports work at the SCCR on new possible norms for copyright limitations and exceptions, particularly as regards to access to knowledge, and uses of new technologies.

Six recent secret ACTA documents

European generic drug companies ask EU Parliament to remove patents from ACTA

The European Generics Association has written to the European Parliament asking that patents be removed from the Anti-Counterfeiting Agreement. A PDF copy of their letter is here. The text in html follows:

MEP Mr. Gianluca Susta
INTA Committee
European Parliament
1049 Bruxelles- Belgium

Brussels, 5th of November 2010

Ref. EGA comments to the consolidated text on ACTA that reflects changes made during the

September 2010 Tokyo round1.

Dear Mr. Susta,

Syndicate content